Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00264693|
Recruitment Status : Completed
First Posted : December 13, 2005
Last Update Posted : January 26, 2010
Low molecular weight heparins (LMWH) have been shown to be at least as efficient and safe as unfractioned heparin (UFH) in prophylaxis and treatment of venous thromboembolic events and in therapy of acute cardiovascular diseases. LMWH are widely used as safe replacement of oral anticoagulation with vitamin K antagonists (VKA).
Due to their pharmacokinetic characteristics, LMWH tend to accumulate in patients with impaired renal function. Official guidelines recommend therefore to use LMWH controlled by Anti-Xa levels or to use UFH instead of LMWH to provide full therapeutic anticoagulation therapy in patients with severe renal insufficiency.
Although dosage recommendations have been proposed for enoxaparin in patients with renal impairment based on several studies, these data cannot be applied to other LMWH directly due to different pharmacokinetic properties of each drug.
The present study aims to clarify the pharmacokinetics of dalteparin in patients with renal insufficiency, especially addressing the question of accumulation after multiple doses and including patients with severe renal insufficiency and derive a safe and suitable concept for using dalteparin in patients with impaired renal function.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||96 participants|
|Official Title:||Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
P - A
Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
P - B
Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
P - C
Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
P - CAPD
Prophylactic Dosage, CAPD
T - A
Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
T - B
Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
T - C
Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
T - CAPD
Therapeutic Dosage, CAPD
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00264693
|Luzern, LU, Switzerland, 6000|
|Principal Investigator:||Pirmin Schmid, MD||Luzerner Kantonsspital, Hematology|
|Study Director:||Andreas G Fischer, MD||Luzerner Kantonsspital, Nephrology|
|Study Chair:||Walter A Wuillemin, MD, PhD||Luzerner Kantonsspital, Hematology|